title: Intravenous application of a primary sevoflurane metabolite improves outcome in murine septic peritonitis: first results.
abstract: Volatile anesthetics are known to have immunomodulatory effects in conditions of organ injury. A recent study in an experimental sepsis model has shown remarkably improved survival when mice were exposed to volatile anesthetics. In the present study, we show that hexafluoroisopropanol - a water-soluble primary sevoflurane metabolite - has beneficial effects on the overall survival in a murine model of cecal ligation and puncture. Seven-day survival as well as tissue damage markers including transaminases and high mobility group box protein-1 were assessed as measures of end organ damage. In animals undergoing cecal ligation and puncture procedure hexafluoroisopropanol conditioning - but not late postconditioning 24 hours after sepsis induction - significantly increased survival rate (17% vs. 77%, p = 0.037) and attenuated secretion of organ damage markers. This study shows survival benefits by administration of the metabolite of a volatile anesthetic. If successfully translated, hexafluoroisopropanol might offer interesting therapeutic opportunities in the future treatment of abdominal sepsis.
authors: Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland ; Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
authors: Inge K
authors: IK
authors: Herrmann
authors: Maricela
authors: M
authors: Castellon
authors: David E
authors: DE
authors: Schwartz
authors: Melanie
authors: M
authors: Hasler
authors: Martin
authors: M
authors: Urner
authors: Guochang
authors: G
authors: Hu
authors: Richard D
authors: RD
authors: Minshall
authors: Beatrice
authors: B
authors: Beck-Schimmer
mesh_terms: D061605:Administration, Intravenous; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D002432:Cecum / Q000473:pathology; D004353:Drug Evaluation, Preclinical; D024243:HMGB1 Protein / Q000097:blood; D007155:Immunologic Factors / Q000008:administration & dosage*; D053208:Kaplan-Meier Estimate; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010538:Peritonitis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D020005:Propanols / Q000008:administration & dosage*; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome; D006845:Hydrocarbons, Fluorinated
chemical_list: D015415:Biomarkers; D024243:HMGB1 Protein; D007155:Immunologic Factors; D020005:Propanols; D000637:Transaminases; C582808:HMGB1 protein, mouse; C001337:hexafluoroisopropanol; D006845:Hydrocarbons, Fluorinated
references: Anesthesiology. 2008 Oct;109(4):651-6
references: 18813044
references: Am J Physiol Renal Physiol. 2007 Sep;293(3):F713-22
references: 17596528
references: Crit Care Med. 2009 Jan;37(1 Suppl):S30-7
references: 19104223
references: Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301
references: 14695889
references: Nat Rev Immunol. 2005 Apr;5(4):331-42
references: 15803152
references: Anesthesiology. 2013 Oct;119(4):901-6
references: 23867232
references: Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1768-73
references: 11734424
references: Ann Surg. 2008 Dec;248(6):909-18
references: 19092335
references: J Cardiothorac Vasc Anesth. 2006 Aug;20(4):477-83
references: 16884976
references: J Intern Med. 2004 Mar;255(3):320-31
references: 14871456
references: Am J Respir Cell Mol Biol. 2011 Sep;45(3):617-24
references: 21239603